Edition:
United States

Asahi Kasei Corp (3407.T)

3407.T on Tokyo Stock Exchange

1,484JPY
23 Jan 2018
Change (% chg)

¥0 (+0.03%)
Prev Close
¥1,484
Open
¥1,490
Day's High
¥1,490
Day's Low
¥1,468
Volume
2,723,900
Avg. Vol
3,844,206
52-wk High
¥1,572
52-wk Low
¥1,004

Chart for

About

ASAHI KASEI CORPORATION is mainly engaged in chemical business. It has seven business segments. The Chemical segment offers petrochemicals, functional films, functional resins and others. The Textile segment offers synthetic textile and nonwoven fabrics. The Housing segment is engaged in the development and sale of housing, as... (more)

Overall

Beta: 0.73
Market Cap(Mil.): ¥2,080,781.00
Shares Outstanding(Mil.): 1,402.62
Dividend: 14.00
Yield (%): 1.89

Financials

  Industry Sector
P/E (TTM): -- 25.97 18.18
EPS (TTM): -- -- --
ROI: -- 16.41 33.32
ROE: -- 21.25 17.09

Asahi Kasei unit wins $400 million U.S. defense contract: Pentagon

WASHINGTON Zoll Medical Corp, a unit of Asahi Kasei Corp, has been awarded a $400 million contract for deployable vital signs monitors, the Pentagon said on Friday.

Dec 08 2017

Asahi Kasei unit wins $400 million U.S. defense contract -Pentagon

WASHINGTON, Dec 8 Zoll Medical Corp, a unit of Asahi Kasei Corp, has been awarded a $400 million contract for deployable vital signs monitors, the Pentagon said on Friday. (Reporting by Mohammad Zargham; Editing by Eric Beech)

Dec 08 2017

Israel's Atox Bio raises $30 mln in Arix Bioscience-led round

JERUSALEM, Dec 4 Israeli biotech firm Atox Bio said on Monday it raised $30 million to further develop its leading product as a kidney treatment, in a fundraising round led by U.K.-based Arix Bioscience.

Dec 04 2017

BRIEF-Bone Therapeutics and Asahi Kasei sign exclusive license agreement for Preob in Japan

* REG-BONE THERAPEUTICS SA AND ASAHI KASEI SIGN EXCLUSIVE LICENSE AGREEMENT FOR PREOB® IN JAPAN

Sep 22 2017

Earnings vs. Estimates